DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Jalah, Rashmi ^a   Kulkarni, Viraj ^a   Patel, Vainav ^a   Rosati, Margherita ^a   Alicea, Candido ^a   Bear, Jenifer ^a   Yu, Lei ^b   Guan, Yongjun ^b   Shen, Xiaoying ^c   Tomaras, Georgia D ^c   LaBranche, Celia ^d   Montefiori, David C ^d   Prattipati, Rajasekhar ^e   Pinter, Abraham ^e   Bess Jr , Julian ^f   Lifson, Jeffrey D ^f   Reed, Steven G ^g   Sardesai, Niranjan Y ^h   Venzon, David J ⁱ   Valentin, Antonio ^a   Pavlakis, George N ^a   Felber, Barbara K ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^h Inovio Pharmaceuticals Inc   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PROTEIN P27; VIRUS ENVELOPE PROTEIN; IMMUNOLOGICAL ADJUVANT; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG POTENTIATION; ELECTROPORATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; LONGEVITY; MALE; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN DETERMINATION; RHESUS MONKEY; SALIVA LEVEL; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ANIMAL; GENETICS; IMMUNOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DNA, VIRAL; ELECTROPORATION; FEMALE; GENE PRODUCTS, ENV; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MACACA MULATTA; MALE; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

EID: 84898716198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091550     Document Type: Article

References (48)

1. Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16: 867-870. (Pubitemid 28405859)
2. Mathiesen I (1999) Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6: 508-514.
3. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R (2006) Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6: 243-273.
4. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, et al. (1999) Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 96: 6417-6422. (Pubitemid 29256680)
5. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, et al. (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164: 4635-4640. (Pubitemid 30238062)
6. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, et al. (2004) Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 22: 2489-2493. (Pubitemid 38757348)
7. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, et al. (2012) Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 7: e29231.
8. Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, et al. (2011) Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 29: 6742-6754.
9. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, et al. (2008) Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 26: 3112-3120.
10. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, et al. (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6: e19252.
11. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, et al. (2013) Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. J Infect Dis 208: 818-829.
12. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, et al. (2008) Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26: 5223-5229.
13. Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, et al. (2006) Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 24: 4503-4509. (Pubitemid 43776779)
14. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, et al. (2007) Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81: 5257-5269. (Pubitemid 46744435)
15. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, et al. (2005) SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 34: 262-270. (Pubitemid 41179588)
16. Schadeck EB, Sidhu M, Egan MA, Chong S-Y, Piacente P, et al. (2006) Plasmid encoded IL-12 functions as a DNA vaccine adjuvant and augments SIVgag-specific cell-mediated and humoral immune responses in Rhesus macaques. Vaccine 24: 4677-4687. (Pubitemid 43776758)
17. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, et al. (2006) A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 24: 4677-4687. (Pubitemid 43776758)
18. Robinson TM, Sidhu MK, Pavlakis GN, Felber BK, Silvera P, et al. (2007) Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses. J Med Primatol 36: 276-284. (Pubitemid 47103491)
19. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, et al. (2008) Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA+IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 180: 7969-7979.
20. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, et al. (2012) IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother 8: 1620-1629.
21. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, et al. (2011) Enhanced control of pathogenic SIVmac239 replication in macaques immunized with a plasmid IL12 and a DNA prime, viral vector boost vaccine regimen. J Virol 85: 9578-9587.
22. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, et al. (2009) DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 06: 15831-15836.
23. Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, et al. (2010) Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28: 4827-4836.
24. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, et al. (2013) DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous SIV challenge. Proc Natl Acad Sci U S A 110: 2975-2980.
25. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
26. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
27. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420.
28. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. (2006) Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348: 341-353.
29. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, et al. (2005) Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34: 226-236. (Pubitemid 41179584)
30. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26: 1098-1110.
31. Kennedy JS, Co M, Green S, Longtine K, Longtine J, et al. (2008) The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26: 4420-4424.
32. Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB (2012) Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 1: 233-240.
33. Jaworski JP, Krebs SJ, Trovato M, Kovarik DN, Brower Z, et al. (2012) Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PLoS One 7: e31464.
34. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, et al. (2013) HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 31: 3747-3755.
35. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
36. Cristillo AD, Weiss D, Hudacik L, Restrepo S, Galmin L, et al. (2008) Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 366: 29-35. (Pubitemid 350297215)
37. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
38. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
39. Rosati M, von Gegerfelt A, Roth P, Alicea C, Valentin A, et al. (2005) DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 79: 8480-8492. (Pubitemid 40853549)
40. Lifson JD, Rossio JL, Piatak M, Jr., Bess J, Jr., Chertova E, et al. (2004) Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 20: 772-787. (Pubitemid 39037509)
41. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, et al. (2009) Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 206: 1117-1134.
42. Kulkarni V, Rosati M, Bear J, Pilkington GR, Jalah R, et al. (2013) Comparison of intradermal and intramuscular delivery of SIV Env DNA by in vivo electroporation in macaques. Hum Vaccin Immunother 9: 2081-94. PMID:23811579.
43. Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, et al. (2013) Vaccination with Vaxfectin adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 viremia. Hum Vaccin Immunother 9: :2069-80 PMID:23820294.
44. Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, et al. (2009) Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 106: 3952-3957.
45. Moore JP, Wallace LA, Follett EA, McKeating JA (1989) An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 3: 155-163. (Pubitemid 19111442)
46. Montefiori DC (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
47. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463.
48. Bolton DL, Song K, Wilson RL, Kozlowski PA, Tomaras GD, et al. (2012) Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol 5: 41-52.